Table 3.
Characteristics and clinicopathological features of 130 young women with early-stage breast cancer according to the surgical treatment.
| Mastectomy | BCS | |
|---|---|---|
| Patients | 38 (29.2%) | 92 (70.8%) |
| Age (years) | 36.7 (25–40) | 36.9 (27–40) |
| Histologic subtype | ||
| - Ductal invasive carcinoma | 36 (94.8%) | 81 (88%) |
| - Lobular invasive carcinoma | 2 (5.2%) | 6 (6.5%) |
| - Others | 0 (%) | 5 (5.5%) |
| Grading | ||
| - 1 | 5 (13.2%) | 13 (14.2%) |
| - 2 | 19 (50%) | 48 (52.2%) |
| - 3 | 14 (36.8%) | 31 (33.6%) |
| Stage | ||
| - pT1mi | 3 (8%) | 3 (3.3%) |
| - pT1a | 5 (13.2%) | 1 (1%) |
| - pT1b | 7 (18.4%) | 26 (28.3%) |
| - pT1c | 23 (60.4%) | 62 (67.4%) |
| - pN0 | 26 (68.5%) | 63 (68.5%) |
| - pN0 (i+) | 0 (%) | 4 (4.4%) |
| - pN1mi | 2 (5.2%) | 11 (11.9%) |
| - pN1 | 10 (26.3%) | 11 (11.9%) |
| - pN2 | 0 (%) | 3 (3.3%) |
| - Multifocal | 18 (47.4%) | 19 (20.7%) |
| Biological subtypes | ||
| - Luminal-like | 27 (71%) | 68 (74%) |
| - HER2-enriched | 4 (10.6%) | 14 (15.2%) |
| - Triple-negative | 7 (18.4%) | 10 (10.9%) |
| Adjuvant treatment | ||
| - Radiotherapy | 7 (18.4%) | 88 (95.6%) |
| - Hormone therapy | 26 (68.5%) | 80 (87%) |
| - Chemotherapy | 22 (57.9%) | 35 (38%) |
| Axillary surgery | ||
| - SLNB | 27 (71%) | 80 (87%) |
| - ALND | 11 (29%) | 12 (13%) |
| BRCA 1 | 9 (23.7%) | 6 (6.5%) |
| BRCA 2 | 1 (2.6%) | 1 (1%) |